Release Source: Oncology Med
Oncology Med Announces Its First Quarter 2007 Unaudited Results
Wednesday June 13, 2007 9:45 am ET
Revenues Increase 32% From Prior Year
PITTSBURGH, PA--(MARKET WIRE)--Jun 13, 2007 -- Oncology Med, Inc. (Other OTC:ONCO.PK - News) announced its unaudited results for the first quarter ended March 31, 2007. Revenues were $ 437,219.65 for the three-month period ended March 31, 2007 which represented a 32% increase from revenues of $ 331,511.84 for the three-month period ended March 31, 2006. Excluding a one-time charge for a prior bad debt, Net Income was $ 33,560.64 for the three-month period ended March 31, 2007 as compared to a Net Loss of $ 39,739.29 for the three-month period ended March 31, 2006.
ADVERTISEMENT
Dr. William J. Walker, chairman of Oncology Med, Inc., stated, "I am extremely pleased with our unaudited results for the first quarter, 2007. We have achieved a substantial increase in revenue over the same period last year which has resulted in net income for the first quarter, 2007. Our roll out of our IMRT program is achieving immediate results as our revenues increase. As clients get more comfortable with the potential revenue increases they will achieve by offering IMRT treatment plans to patients, their use of IMRT treatment programs will increase which should result in our continuing growth."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation plans to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at www.oncologymed.com.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.
Contact:
For information, please contact:
Mr. Trevor Bentley
Investor Communications
Bentley Communications
1-888-818-8738
Email Contact
--------------------------------------------------------------------------------
Source: Oncology Med
AI
Market Data 
Markets 
